140 related articles for article (PubMed ID: 23555577)
1. Identification of relevant conformational epitopes on the HER2 oncoprotein by using Large Fragment Phage Display (LFPD).
Gabrielli F; Salvi R; Garulli C; Kalogris C; Arima S; Tardella L; Monaci P; Pupa SM; Tagliabue E; Montani M; Quaglino E; Stramucci L; Curcio C; Marchini C; Amici A
PLoS One; 2013; 8(3):e58358. PubMed ID: 23555577
[TBL] [Abstract][Full Text] [Related]
2. In silico design of discontinuous peptides representative of B and T-cell epitopes from HER2-ECD as potential novel cancer peptide vaccines.
Manijeh M; Mehrnaz K; Violaine M; Hassan M; Abbas J; Mohammad R
Asian Pac J Cancer Prev; 2013; 14(10):5973-81. PubMed ID: 24289611
[TBL] [Abstract][Full Text] [Related]
3. Linear and conformational B cell epitope prediction of the HER 2 ECD-subdomain III by in silico methods.
Mahdavi M; Mohabatkar H; Keyhanfar M; Dehkordi AJ; Rabbani M
Asian Pac J Cancer Prev; 2012; 13(7):3053-9. PubMed ID: 22994709
[TBL] [Abstract][Full Text] [Related]
4. Predicted B-cell epitopes of HER-2 oncoprotein by a bioinformatics method: a clue for breast cancer vaccine development.
Wiwanitkit V
Asian Pac J Cancer Prev; 2007; 8(1):137-8. PubMed ID: 17477789
[TBL] [Abstract][Full Text] [Related]
5. Phage-Based Anti-HER2 Vaccination Can Circumvent Immune Tolerance against Breast Cancer.
Bartolacci C; Andreani C; Curcio C; Occhipinti S; Massaccesi L; Giovarelli M; Galeazzi R; Iezzi M; Tilio M; Gambini V; Wang J; Marchini C; Amici A
Cancer Immunol Res; 2018 Dec; 6(12):1486-1498. PubMed ID: 30327365
[TBL] [Abstract][Full Text] [Related]
6. Discovery of epitopes for targeting the human epidermal growth factor receptor 2 (HER2) with antibodies.
Rockberg J; Schwenk JM; Uhlén M
Mol Oncol; 2009 Jun; 3(3):238-47. PubMed ID: 19393584
[TBL] [Abstract][Full Text] [Related]
7. Epitope mapping of neutralizing botulinum neurotoxin A antibodies by phage display.
Mullaney BP; Pallavicini MG; Marks JD
Infect Immun; 2001 Oct; 69(10):6511-4. PubMed ID: 11553596
[TBL] [Abstract][Full Text] [Related]
8. Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities.
Dakappagari NK; Lute KD; Rawale S; Steele JT; Allen SD; Phillips G; Reilly RT; Kaumaya PT
J Biol Chem; 2005 Jan; 280(1):54-63. PubMed ID: 15507452
[TBL] [Abstract][Full Text] [Related]
9. Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α.
Ceran C; Cokol M; Cingoz S; Tasan I; Ozturk M; Yagci T
BMC Cancer; 2012 Oct; 12():450. PubMed ID: 23033967
[TBL] [Abstract][Full Text] [Related]
10. Induction of protective anti-CTL epitope responses against HER-2-positive breast cancer based on multivalent T7 phage nanoparticles.
Pouyanfard S; Bamdad T; Hashemi H; Bandehpour M; Kazemi B
PLoS One; 2012; 7(11):e49539. PubMed ID: 23166703
[TBL] [Abstract][Full Text] [Related]
11. In silico proteomic characterization of human epidermal growth factor receptor 2 (HER-2) for the mapping of high affinity antigenic determinants against breast cancer.
Baloria U; Akhoon BA; Gupta SK; Sharma S; Verma V
Amino Acids; 2012 Apr; 42(4):1349-60. PubMed ID: 21229277
[TBL] [Abstract][Full Text] [Related]
12. Identification of B-cell epitopes of Borrelia burgdorferi outer surface protein C by screening a phage-displayed gene fragment library.
Pulzova L; Flachbartova Z; Bencurova E; Potocnakova L; Comor L; Schreterova E; Bhide M
Microbiol Immunol; 2016 Oct; 60(10):669-677. PubMed ID: 27619624
[TBL] [Abstract][Full Text] [Related]
13. A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses.
Dakappagari NK; Pyles J; Parihar R; Carson WE; Young DC; Kaumaya PT
J Immunol; 2003 Apr; 170(8):4242-53. PubMed ID: 12682258
[TBL] [Abstract][Full Text] [Related]
14. Advancement and applications of peptide phage display technology in biomedical science.
Wu CH; Liu IJ; Lu RM; Wu HC
J Biomed Sci; 2016 Jan; 23():8. PubMed ID: 26786672
[TBL] [Abstract][Full Text] [Related]
15. Production and Characterization of New Anti-HER2 Monoclonal Antibodies.
Mahdavi M; Keyhanfar M; Jafarian A; Mohabatkar H; Rabbani M
Monoclon Antib Immunodiagn Immunother; 2015 Jun; 34(3):213-21. PubMed ID: 26090600
[TBL] [Abstract][Full Text] [Related]
16. Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design.
Yip YL; Smith G; Koch J; Dübel S; Ward RL
J Immunol; 2001 Apr; 166(8):5271-8. PubMed ID: 11290813
[TBL] [Abstract][Full Text] [Related]
17. Antigenic and immunogenic mimicry of the HER2/neu oncoprotein by phage-displayed peptides.
Orlandi R; Ménard S; Colnaghi MI; Boyer CM; Felici F
Eur J Immunol; 1994 Nov; 24(11):2868-73. PubMed ID: 7525309
[TBL] [Abstract][Full Text] [Related]
18. Identification of three novel B-cell epitopes of VMH protein from Vibrio mimicus by screening a phage display peptide library.
Xiao N; Cao J; Zhou H; Ding SQ; Kong LY; Li JN
Vet Immunol Immunopathol; 2016 Dec; 182():22-28. PubMed ID: 27863546
[TBL] [Abstract][Full Text] [Related]
19. A linear region of a monoclonal antibody conformational epitope mapped on p185HER2 oncoprotein.
Orlandi R; Formantici C; Ménard S; Boyer CM; Wiener JR; Colnaghi M
Biol Chem; 1997 Nov; 378(11):1387-92. PubMed ID: 9426199
[TBL] [Abstract][Full Text] [Related]
20. Polyclonal antibodies against gp185HER2 peptides: their putative role in the identification of a particular HER2 status in patients with breast cancer.
Di Modugno F; Buglioni S; Mottolese M; Bello DD; Cascioli S; Chersi A; Santoni A; Nisticò P
J Immunother; 2001; 24(3):221-31. PubMed ID: 11394499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
